文献速递精神分裂症与精神病性障碍心境障碍

精神病性障碍中的多巴胺与心境:18F-DOPA PET研究

Dopamine and Mood in Psychotic Disorders: An 18F-DOPA PET Study.
PubMed 文献 · JAMA Psychiatry · 2025-08-13

该横断面研究纳入38例首发精神病伴情感综合征患者(25例当前重性抑郁发作,13例混合/躁狂综合征)和38名匹配对照,用18F-DOPA PET测量纹状体多巴胺合成能力(Kicer)。伴重性抑郁发作者Kicer低于混合/躁狂综合征者,差异在边缘纹状体最大;整体精神病样本中较高Kicer与更严重阳性症状相关,关联见于联合纹状体而非边缘纹状体。

要点

  • 精神病伴重性抑郁发作者纹状体Kicer低于伴混合/躁狂综合征者,边缘纹状体差异最大。
  • 精神病样本中较高纹状体Kicer与更重阳性症状相关,关联见于联合纹状体。
  • 边缘纹状体Kicer与阳性症状无显著关联。

核心结论

  • 精神病伴重性抑郁发作者的Kicer低于伴混合/躁狂综合征者。
  • 跨诊断来看,更重阳性精神病性症状与联合纹状体更高Kicer相关,而非边缘纹状体。

研究设计与样本

  • 横断面研究,使用18F-DOPA PET测量纹状体Kicer。
  • 共76人:38例首发精神病伴情感综合征(25例重性抑郁发作,13例混合/躁狂综合征)和38名匹配对照。
  • 受试者来自英国伦敦市中心早期干预服务,数据收集于2013年3月至2022年2月。

主要发现

  • 控制年龄和性别后,全纹状体Kicer组间差异显著(F2,71=4.04;P=.02;R2=0.13)。
  • 精神病伴重性抑郁发作者Kicer低于伴混合/躁狂综合征者(β[SE]=0.014[0.001];P=.02),边缘纹状体差异最大(Cohen d=1.57;P<.001)。
  • 整体精神病样本中,较高纹状体Kicer与更重阳性症状相关(R2=0.13;β[SE]=0.000066[0.000030];P=.03),联合纹状体关联显著(R2=0.15;P=.02)。
  • 边缘纹状体未发现显著关联。

关键数值与推荐

  • Kicer为纹状体多巴胺合成能力指标,由18F-DOPA PET测量。
  • 症状评估采用阳性与阴性症状量表、汉密尔顿抑郁量表、蒙哥马利-奥斯伯格抑郁量表和年轻躁狂量表。

临床怎么用

  • 精神病伴抑郁症状者纹状体多巴胺合成能力较低,提示多巴胺调节治疗需考虑情感状态。
  • 阳性症状严重度与联合纹状体多巴胺合成能力相关,或为多巴胺调节药物研发提供亚区靶点。

局限性

  • 横断面设计无法推断多巴胺功能与情感综合征的因果方向。
  • 样本量较小(76人),混合/躁狂综合征亚组仅13例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is limited neurobiological or trial evidence guiding treatment of comorbid affective syndromes in psychotic disorders. Given the use of dopamine-blocking antipsychotics, understanding dopamine function across these mood states is warranted. OBJECTIVE: To test for differences in dopamine synthesis capacity (Kicer) between affective syndromes across psychotic disorders and for association with psychotic symptom severity. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study using fluorine F 18-labeled fluorodopa (18F-DOPA) positron emission tomography (PET), individuals with first-episode psychosis and comorbid affective syndromes, including a current major depressive episode (MDE) or mixed/mania syndromes, and matched controls were recruited from early intervention services in inner-city London, United Kingdom. Data were collected from March 2013 to February 2022 and analyzed from October 1, 2023, to January 1, 2025. EXPOSURE: Striatal Kicer measured by 18F-DOPA PET. MAIN OUTCOMES AND MEASURES: Striatal Kicer and scores on the Positive and Negative Syndrome Scale, Hamilton Depression Rating Scale, Montgomery-Åsberg Depression Rating Scale, and Young Mania Rating Scale were determined. RESULTS: The study included a total of 76 individuals (38 with first-episode psychosis and comorbid affective syndromes [25 with MDE and 13 with mixed/mania syndromes] and 38 matched controls). The mean (SD) age was 27.2 (8.9) years overall, 30.7 (12.8) years among those with MDE, 23.7 (3.1) years among those with mixed/mania syndromes, and 26.0 (6.0) years among controls. Sex distribution did not differ (MDE, 13 [52%] male; mixed/mania syndromes, 8 [62%] male; controls, 25 [66%] male; P = .56). Kicer (controlling for age and sex) was significant across groups in whole striatum (F2,71 = 4.04; P = .02; R2 = 0.13). People with psychosis and MDE had lower Kicer compared with those with psychosis and mixed/mania syndromes (β [SE], 0.014 [0.001]; P = .02), with the largest difference observed in the limbic striatum (Cohen d = 1.57; P < .001). In the overall psychosis sample, higher striatal Kicer was associated with greater positive psychotic symptoms (R2 = 0.13; β [SE], 0.000066 [0.000030]; P = .03), notably in the associative striatum (R2 = 0.15; P = .02). No significant association was found in the limbic striatum. CONCLUSIONS AND RELEVANCE: Kicer was lower in psychosis and comorbid MDE than mixed/mania syndromes, and transdiagnostically, greater positive psychotic symptoms were associated with higher Kicer in the associative, but not limbic, striatum. This subregion dopamine dysregulation has relevance for dopamine-modulating therapeutic agents and drug discovery.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jauhar S, McCutcheon RA, Nour MM, et al. Dopamine and Mood in Psychotic Disorders: An 18F-DOPA PET Study. JAMA Psychiatry. 2025. PMID: 40802251. doi:10.1001/jamapsychiatry.2025.1811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。